IceCure Medical Ltd (ICCM)
Automate Your Wheel Strategy on ICCM
With Tiblio's Option Bot, you can configure your own wheel strategy including ICCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ICCM
- Rev/Share 0.0591
- Book/Share 0.1242
- PB 8.2106
- Debt/Equity 0.0665
- CurrentRatio 1.9503
- ROIC -2.1282
- MktCap 57700380.0
- FreeCF/Share -0.227
- PFCF -4.5764
- PE -3.7068
- Debt/Assets 0.0365
- DivYield 0
- ROE -1.5637
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
IceCure Announces Record Date for Rights Offering for Up to $10 Million
Published: June 25, 2025 by: PRNewsWire
Sentiment: Neutral
CAESAREA, Israel , June 25, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its board of directors approved a rights offering (the "Rights Offering") to all holders of record of the Company's ordinary shares as of 5:00 p.m.
Read More
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
Published: May 21, 2025 by: PRNewsWire
Sentiment: Neutral
CAESAREA, Israel , May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025.
Read More
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
Breast surgeons expressed strong interest in participating in IceCure's planned post-market study for ProSense® in the treatment of early-stage breast cancer ICE3 study named as one of the "Best Papers of 2024" Cryoablation was mentioned favorably during the ASBrS Presidential Address CAESAREA, Israel , May 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it participated in the American Society of Breast Surgeons (ASBrS) 2025 Annual Meeting on April 30 – May 4, 2025 in …
Read More
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study plan IceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting ProSense® would become the first-in-class minimally invasive choice—a major advancement in women's health and a new paradigm in breast cancer care as a simple out-patient procedure U.S. sales and distribution team ready to drive sales of ProSense® systems and disposable probes—supporting medical community and patients looking for a new minimally invasive option to lumpectomy …
Read More
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
Two sold-out SBI breast cryoablation courses featured hands-on training with ProSense® IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a specialist in women's imaging and breast cryoablation CAESAREA, Israel , April 28, 2025 /PRNewswire/ -- IceCure Medical Ltd.
Read More
IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript
Published: March 27, 2025 by: Seeking Alpha
Sentiment: Neutral
IceCure Medical Ltd (NASDAQ:ICCM ) Q4 2024 Earnings Conference Call March 27, 2025 10:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer and Director Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Anthony Vendetti - Maxim Group Operator Good morning, and thank you for standing by. Currently, all the participants' are in a listen-only mode.
Read More
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel , March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024.
Read More
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel , March 20, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it is in continued discussions with the U.S. Food and Drug Administration ("FDA") regarding its De Novo marketing authorization request for ProSense® in early-stage low risk breast cancer with endocrine therapy.
Read More
About IceCure Medical Ltd (ICCM)
- IPO Date 2021-08-26
- Website https://www.icecure-medical.com
- Industry Medical - Devices
- CEO Eyal Shamir
- Employees 64